Epigenetic drug discovery is one of the fastest growing and potentially groundbreaking target spaces for developers. Over the past few years, a significant increase in small molecule inhibitors chemically modulating enzymatic activity of Histone Methyltransferases (HMTs), Histone Demethylases (HDMs), and disrupting interactions of the BET family bromodomains have rapidly translated into clinical investigation. Now, with apparent safety and efficacy being demonstrated in clinical trials, the opportunity to develop novel chemical tools and inhibitors against the wealth of epigenetic modifiers is ever present. Cambridge Healthtech Institute will once again convene leaders in Epigenetic Inhibitor Discovery to bring forth novel and emerging strategies for inhibition, new bioactive tools and inhibitors, as well as strategies for lead optimization to obtain clinically relevant small molecules. Join fellow drug discovery scientists for this day-and-a-half meeting that is in the first half of CHI’s larger Drug Discovery Chemistry event.
- Conferences
- Epigenetic Inhibitor Discovery 2015
Epigenetic Inhibitor Discovery 2015
Cambridge Healthtech Institute - 21 Apr 2015
Summary
Topics
Details
Meeting Summary
Topics Include
Meeting Details
Date | 21 Apr 2015 |
Location | Hilton San Diego Resort & Spa San Diego, CA, USA Get Directions |
Organizers | Kip Harry |